OA 09.06 – A Phase Ib trial of savolitinib plus gefitinib for Chinese patients with EGFR-mutant MET-amplified advanced NSCLC (WCLC 2017)

Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Handzel, M.M. Frigault, G. Ahmed, C. Egile, S. Morgan, Yi-Long Wu


Venue: IASLC 18th World Conference on Lung Cancer in Yokohama, Japan
Session: OA 09 – EGFR TKI Resistance (ID 663)
Presenter: Jin-Ji Yang
Date: Tuesday, October 17, 2017


For a summary of the data presented, please see the Chi-Med company overview presentation.